ATE284214T1 - Imidazo(1,2-a)-pyridinderivate als mglur5 antagonisten - Google Patents

Imidazo(1,2-a)-pyridinderivate als mglur5 antagonisten

Info

Publication number
ATE284214T1
ATE284214T1 AT02737889T AT02737889T ATE284214T1 AT E284214 T1 ATE284214 T1 AT E284214T1 AT 02737889 T AT02737889 T AT 02737889T AT 02737889 T AT02737889 T AT 02737889T AT E284214 T1 ATE284214 T1 AT E284214T1
Authority
AT
Austria
Prior art keywords
imidazo
pyridine derivatives
mglur5 antagonists
mglur5
antagonists
Prior art date
Application number
AT02737889T
Other languages
English (en)
Inventor
Vincent Mutel
Jens-Uwe Peters
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE284214T1 publication Critical patent/ATE284214T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT02737889T 2001-03-27 2002-03-20 Imidazo(1,2-a)-pyridinderivate als mglur5 antagonisten ATE284214T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01107562 2001-03-27
PCT/EP2002/003098 WO2002092086A1 (en) 2001-03-27 2002-03-20 Imidazo (1,2-a)-pyridine derivatives as mglur5 antagonists

Publications (1)

Publication Number Publication Date
ATE284214T1 true ATE284214T1 (de) 2004-12-15

Family

ID=8176948

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02737889T ATE284214T1 (de) 2001-03-27 2002-03-20 Imidazo(1,2-a)-pyridinderivate als mglur5 antagonisten

Country Status (17)

Country Link
US (3) US6596731B2 (de)
EP (1) EP1381363B1 (de)
JP (1) JP4088162B2 (de)
KR (1) KR100557847B1 (de)
CN (1) CN1529597A (de)
AR (2) AR037488A1 (de)
AT (1) ATE284214T1 (de)
AU (1) AU2002312768B2 (de)
BR (1) BR0208387A (de)
CA (1) CA2439291C (de)
DE (1) DE60202200T2 (de)
DK (1) DK1381363T3 (de)
ES (1) ES2232756T3 (de)
MX (1) MXPA03008525A (de)
PT (1) PT1381363E (de)
WO (1) WO2002092086A1 (de)
ZA (1) ZA200306341B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596731B2 (en) * 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
WO2003055479A1 (en) * 2001-12-21 2003-07-10 Consejo Superior De Investigaciones Cientificas Compounds and their therapeutic use related to the phosphorylating activity of the enzyme gsk-3
JPWO2004035522A1 (ja) * 2002-08-30 2006-02-16 株式会社 ビーエフ研究所 プリオン蛋白蓄積性疾患の診断プローブおよび治療薬ならびにプリオン蛋白の染色剤
US7105533B2 (en) * 2002-09-13 2006-09-12 Merck & Co., Inc. Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
DE10247271A1 (de) * 2002-10-10 2004-08-26 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yle
ITMI20030151A1 (it) * 2003-01-30 2004-07-31 Recordati Ind Chimica E Farma Ceutica S P A Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
US7531529B2 (en) * 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
US7429590B2 (en) 2003-12-10 2008-09-30 Merck & Co. Inc. Antiprotozoal imidazopyridine compounds
HRP20080363T3 (hr) 2004-06-01 2008-09-30 F. Hoffmann - La Roche Ag Piridin-4-il-etinil-imidazoli i pirazoli kao antagonisti mglu5 receptora
PT1863818E (pt) * 2005-03-23 2010-04-09 Hoffmann La Roche Derivados de acetilenil-pirazolo-pirimidina como antagonistas de mglur2
ATE463495T1 (de) 2005-09-27 2010-04-15 Hoffmann La Roche Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
HUP0500920A2 (en) * 2005-10-05 2007-07-30 Richter Gedeon Nyrt Oxadiazole derivatives, process for their preparation and their use
EP1966201A1 (de) * 2005-11-28 2008-09-10 Mallinckrodt, Inc. Verbessertes verfahren zur herstellung von imidazolpyridinen
KR101062583B1 (ko) * 2006-01-17 2011-09-06 에프. 호프만-라 로슈 아게 Ｇａｂａ 수용체에 의해 알츠하이머병의 치료에 유용한아릴-아이속사졸-4-일-이미다조[1,2-ａ]피리딘
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200803903A (en) * 2006-04-28 2008-01-16 Nihon Mediphysics Co Ltd Novel compound having affinity to amyloid
JP5238496B2 (ja) * 2006-05-19 2013-07-17 日本メジフィジックス株式会社 新規アミロイド親和性化合物
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
CN101501033B (zh) * 2006-06-21 2012-08-01 通用电气医疗有限公司 对淀粉状蛋白具有亲和性的化合物
TW200819458A (en) * 2006-06-23 2008-05-01 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
US20100056826A1 (en) * 2006-11-09 2010-03-04 Nihon Medi-Physicis Co., Ltd. Radioactive diagnostic imaging agent
WO2008059714A1 (en) * 2006-11-17 2008-05-22 Nihon Medi-Physics Co., Ltd. Novel compounds with affinity for amyloid
CN101595108A (zh) * 2006-11-30 2009-12-02 日本医事物理股份有限公司 对淀粉状蛋白具有亲和性的新化合物
EP2119458B9 (de) 2007-02-13 2013-08-21 Nihon Medi-Physics Co., Ltd. Verfahren zur herstellung eines abbildungsmittels zur strahlendiagnose
TW200901998A (en) 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
WO2009019708A2 (en) * 2007-08-09 2009-02-12 Urifer Ltd Pharmaceutical compositions and methods for the treatment of cancer
TW200922566A (en) 2007-09-14 2009-06-01 Ortho Mcneil Janssen Pharm 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
EA017648B1 (ru) 2007-09-14 2013-02-28 Орто-Макнейл-Янссен Фармасьютикалз, Инк. 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
BRPI0816970A2 (pt) 2007-09-14 2015-03-24 Ortho Mcneil Janssen Pharm 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
TW200918102A (en) * 2007-10-24 2009-05-01 Nihon Mediphysics Co Ltd Novel compound having affinity for amyloid
KR20100101577A (ko) * 2007-10-30 2010-09-17 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물의 사용 및 제조 방법
JPWO2009057577A1 (ja) * 2007-10-30 2011-03-10 日本メジフィジックス株式会社 新規アミロイド親和性化合物の使用及び製造方法
KR20100089858A (ko) * 2007-10-30 2010-08-12 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물의 사용 및 제조 방법
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
CA2704436C (en) 2007-11-14 2016-01-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2090576A1 (de) * 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-Pyrazolo[1,5-a]pyridin-Verbindungen, Verfahren zu ihrer Herstellung und Verwendung als Modulatoren des Metabotropen Glutamatrezeptoren (mGluR)
US20110065728A1 (en) 2008-05-14 2011-03-17 Otsuka Pharmaceutical Factory, Inc. Lipoprotein lipase-activating compositions comprising benzene derivatives
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) * 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
HRP20131122T1 (hr) 2009-05-12 2013-12-20 Janssen Pharmaceuticals, Inc. Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
MY153913A (en) * 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
EP2661435B1 (de) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazol[4,3-a]pyridinderivate und ihre verwendung als positive allosterische mglur2-rezeptormodulatoren
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
WO2015036618A1 (en) 2013-09-16 2015-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of epilepsy
PL3096790T3 (pl) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
ME03518B (de) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinationen mit positiven allosterischen modulatoren von metabotropem glutamatergen rezeptor vom subtyp 2 und deren verwendung
TWI713497B (zh) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
CA2999852A1 (en) 2015-09-29 2017-04-06 Oncotherapy Science, Inc. Bicyclic compound and use thereof for inhibiting suv39h2
KR102797127B1 (ko) 2018-12-29 2025-04-21 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 헤테로고리계 화합물, 중간체, 이의 제조 방법 및 용도
CN113387946B (zh) * 2021-05-17 2023-08-01 衡阳师范学院 一种超声辅助多组分合成2-苯基-3-芳胺甲基咪唑并吡啶衍生物的方法
EP4265248A1 (de) * 2022-04-22 2023-10-25 Université Paris Cité Verbindungen, die die produktion von proteinen durch immunzellen induzieren

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3701780A (en) 1970-09-18 1972-10-31 Merck & Co Inc Imidazo(1,2-a)pyridines
JPS5341678B2 (de) 1974-03-22 1978-11-06
CH590862A5 (en) 1974-02-26 1977-08-31 Ciba Geigy Ag Isothiocyanato-substd. (2)-phenyl-imidazo (1,2-a)-pyridines prodn. - from corresp. amine and thiocarbonic acid derivs., useful as anthelmintics
JPS514194A (en) 1974-06-28 1976-01-14 Yoshitomi Pharmaceutical Imidazopirijinjudotaino seiho
JPS51125095A (en) 1974-07-23 1976-11-01 Yoshitomi Pharmaceut Ind Ltd A process for rreparing alcohol derivatives.
FR2492382A1 (fr) 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
FR2525601A1 (fr) 1982-04-21 1983-10-28 Synthelabo Derives d'imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
FR2525602A1 (fr) 1982-04-21 1983-10-28 Synthelabo Imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
FR2568880B1 (fr) 1984-08-07 1986-12-12 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
DE3446778A1 (de) 1984-12-21 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
FR2581646B1 (fr) 1985-05-07 1987-09-18 Synthelabo Derives d'imidazopyridine, leur preparation et leur application en therapeutique
ATE62687T1 (de) 1986-01-22 1991-05-15 Synthelabo Acylaminomethylimidazo(1,2-a>pyrimidinderivate, ihre herstellung und therapeutische verwendung.
FR2600650B1 (fr) 1986-06-27 1988-09-09 Synthelabo Procede de preparation d'imidazopyridines et composes intermediaires
FR2606410B1 (fr) 1986-11-07 1989-02-24 Synthelabo Imidazopyridines, leur preparation et leur application en therapeutique
EP0533837A4 (en) 1990-06-12 1994-11-17 Smithkline Beecham Corp Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases
IN179790B (de) * 1992-02-10 1997-12-06 Council Scient Ind Res
IN179788B (de) * 1992-02-10 1997-12-06 Council Scient Ind Res
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
JPH11116481A (ja) 1997-10-06 1999-04-27 Sumitomo Pharmaceut Co Ltd スタット６活性化阻害剤
ES2151834B1 (es) 1998-08-06 2001-08-16 Sint Quimica Sa Procedimiento para preparar n,n,6-trimetil-2-(4-metilfenil)-imidazo-(1,2-a)-piridina-3-acetamida y sus sales.
AU2001249679A1 (en) 2000-03-31 2001-10-15 Ortho-Mcneil Pharmaceutical, Inc. Phenyl-substituted imidazopyridines
US6596731B2 (en) * 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives

Also Published As

Publication number Publication date
US6916826B2 (en) 2005-07-12
BR0208387A (pt) 2004-06-15
PT1381363E (pt) 2005-04-29
US6861437B2 (en) 2005-03-01
US6596731B2 (en) 2003-07-22
DE60202200T2 (de) 2005-12-15
DE60202200D1 (de) 2005-01-13
KR100557847B1 (ko) 2006-03-10
EP1381363A1 (de) 2004-01-21
EP1381363B1 (de) 2004-12-08
CN1529597A (zh) 2004-09-15
ZA200306341B (en) 2004-11-15
JP2004525192A (ja) 2004-08-19
US20020188128A1 (en) 2002-12-12
ES2232756T3 (es) 2005-06-01
MXPA03008525A (es) 2003-12-08
JP4088162B2 (ja) 2008-05-21
CA2439291C (en) 2008-01-08
AR062387A2 (es) 2008-11-05
DK1381363T3 (da) 2005-04-18
KR20030083013A (ko) 2003-10-23
WO2002092086A1 (en) 2002-11-21
AR037488A1 (es) 2004-11-17
US20040180921A1 (en) 2004-09-16
AU2002312768B2 (en) 2007-06-21
CA2439291A1 (en) 2002-11-21
US20030212096A1 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
DE60202200D1 (de) Imidazo[1,2-a]-pyridinderivate als mglur5 antagonisten
ATE354570T1 (de) 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten
IS7323A (is) 2-(pýridín-2-ýlamínó)-pýridó[2,3-d]pýrimidín-7-ón
ATE466012T1 (de) Pyrazolo 3,4-b pyridinverbindungen und ihre verwendung als phosphodiesterase inhibitoren
PT1218378E (pt) Derivados de terc-butil-(7-metil-imidazo-¬1,2-a|-piridin-3-il)-amina
DE60216115D1 (de) BENZIMIDAZO 4,5-föISOCHINOLINON-DERIVATE
DE60214428D1 (de) 1, 4-dihydro-1, 4-diphenylpyridin-derivate
NO20043064L (no) 1-alkyl-1-azoniabisyklo [2.2.2] oktankarbamatderivater og anvendelse av disse som muskarine reseptorantagonister
ATE381565T1 (de) 1,3,8-triaza-spiro 4,5 decan-4-onderivative als neurokininrezeptorantagonisten
DK1427709T3 (da) 3-substituerede 4-pyrimidonderivater
DE60207241D1 (de) 5-amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidin-derivate
ATE433977T1 (de) Substituierte 8-perfluoro-6,7,8,9- tetrahydropyrimido 1,2-a pyrimidin-4-on-derivate
DK1608654T3 (da) 8-substituerede-6, 7, 8, 9-tetrahydropyrimido (1,2- a) pyrimidin-4-on-derivater
ATE309247T1 (de) Heteroaryl substituierte 2-pyridinyl und 2- pyrimidinyl-6,7,8,9-tetrahydropyrimido(1,2- a)pyrimidin-4-onderivate
DE60008262D1 (de) Piperazinderivate als 5-ht1b antagonisten
DE60205921D1 (de) SUBSTITUIERTE 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDOç1,2-A!PYRIMIDIN-4-ON- UND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO-ç1,2-A!PYRIMIDIN-5(1H)ONDERIVATE
ATE326467T1 (de) Imidazo 1,2-aöpyridine
DE60114852D1 (de) Chinazolin-derivate als alpha-1 adrenerge antagonisten
ATE309994T1 (de) Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten
ATE286018T1 (de) Biphenylderivate als neurokinin-1 antagonisten
DE60214408D1 (de) 5-METHOXY-8-ARYL-i1,2,4öTRIAZOLOi1,5-AöPYRIDINE DERIVATIVE ALS ADENOSIN-REZEPTOR ANTAGONISTEN
DE60210058D1 (de) Alkoxycarbonylamino-heteroaryl-carbonsäurederivate als ip-antagonisten
NO20042980L (no) 3,4-dihydro-1H-isokinolin-2-yl-derivater
DE60012953D1 (de) 3-amino-2-phenylpiperidinderivate als substanz p antagonisten
NO20031412D0 (no) Substituerte 3,4-dihydro-pyrido[1,2-A]pyrimidiner

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1381363

Country of ref document: EP

REN Ceased due to non-payment of the annual fee